The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 1 of 5

| 1 | 2 | 3 | 4 | 5 | Next

Time/Date Code Headline Source Impact
16:00 23-May-2016 AZN Director/PDMR Shareholding RNS +1.00% Up
07:00 18-May-2016 AZN TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL RNS -0.67% Down
07:00 17-May-2016 AZN POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA RNS -0.80% Down
07:00 12-May-2016 AZN SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US RNS +0.79% Up
17:30 11-May-2016 AZN Publication of Final Terms RNS +1.48% Up
17:35 09-May-2016 AZN Launch and pricing of EUR2.2bn bond issues RNS +2.27% Up
15:00 05-May-2016 AZN Publication of a Prospectus RNS -0.65% Down
13:30 03-May-2016 AZN Total Voting Rights RNS -2.81% Down
07:01 03-May-2016 AZN AstraZeneca completes divestment of Imdur RNS -2.81% Down
07:00 03-May-2016 AZN AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY RNS -2.81% Down
17:30 29-Apr-2016 AZN Result of AGM RNS -3.99% Down
12:46 29-Apr-2016 AZN POSITIVE CHMP OPINION FOR CAZ AVI RNS -3.99% Down
07:00 29-Apr-2016 AZN AZN: 1st Quarter Results RNS -3.99% Down
09:00 28-Apr-2016 AZN Notice of Results RNS -4.00% Down
09:29 26-Apr-2016 AZN AZ enters US licensing agreement with Ironwood RNS -3.90% Down
07:01 26-Apr-2016 AZN BEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD RNS -3.90% Down
07:00 08-Apr-2016 AZN AZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL RNS +1.78% Up
11:30 01-Apr-2016 AZN Total Voting Rights RNS +3.04% Up
07:00 29-Mar-2016 AZN TAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS RNS +0.06% Up
15:00 24-Mar-2016 AZN Director/PDMR Shareholding RNS -0.22% Down

 Page 1 of 5

| 1 | 2 | 3 | 4 | 5 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address 2 Kingdom Street, London, W2 6BD, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 49,954.23
Listing/Admission to trading 01 Jun 1993
Trading service SETS
Market MAINMARKET
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
25-May-16
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 500
SEDOL 0989529
ISIN number GB0009895292



ASTRAZENECA share news analysis (AZN)